Protara Therapeutics is trading 12.7% down at $3.50 in pre-market sessions despite a lack of fresh company-specific catalysts.
- The sharp decline marks a reversal from the stock's recent gradual gains and appears to be an isolated move.
- No earnings reports, FDA updates, or major analyst actions have been reported this morning, while broader U.S. indices are trading slightly higher.